Mostly True, But Wrong on the Numbers — CAR T-Cell Therapy Did Achieve Remission in Lupus Patients, Just Not '5 of 6'
“Five of six lupus patients receiving a lower dose of CAR T-cell therapy achieved remission within months”
The argument in brief
A claim circulating online says five of six lupus patients given a lower dose of CAR T-cell therapy achieved remission within months. The real science is genuinely remarkable, but the numbers are wrong: the landmark 2022 study in Nature Medicine treated five patients — not six — and all five achieved drug-free remission. The 'lower dose' framing also has no clear basis in the published research.
Data: Nature Medicine, Mackensen et al. 2022 & Georg et al. 2024
Why it spread
The genuine science here is extraordinary and received wide media coverage, which means millions of people encountered it through secondhand summaries rather than the original papers. In that game of telephone, a clean '5 out of 5' result may have become '5 out of 6' through a simple misread, and the 'lower dose' detail was likely added because it makes the therapy sound less risky and more likely to reach patients soon — an emotionally appealing spin on an already hopeful story.
The claim states that five out of six lupus patients who received a lower dose of CAR T-cell therapy went into remission within months. The core of this is real — CAR T-cell therapy is producing dramatic results in lupus patients — but the specific numbers and framing are inaccurate in ways that matter.
The original landmark study, published in Nature Medicine by Mackensen et al. in 2022, enrolled five patients with severe systemic lupus erythematosus. All five achieved drug-free remission. That is a 5-out-of-5 result, not 5-out-of-6. The distinction is small but meaningful: a perfect early result is scientifically different from a near-miss, and accuracy builds the trust that good science deserves.
The 'lower dose' detail is also unsupported. Science magazine's coverage of the Mackensen group's work did not describe the treatment as a lower dose relative to any comparison group. No published trial result matching a specific 'lower dose' arm with a '5 of 6' outcome is identifiable in the registered trial data on ClinicalTrials.gov. This framing appears to have been added somewhere along the way, possibly to make the therapy sound safer or more accessible.
The follow-up research only strengthens the genuine story. A 2024 Nature Medicine study by Georg et al. from the same Erlangen group expanded the cohort to 15 patients and found 14 achieved low disease activity or remission. Expanded reporting in The Lancet confirmed high remission rates across autoimmune disease trials. This is a legitimate scientific breakthrough — it just does not need embellishment.
This kind of distortion spreads because the underlying story is so compelling. Exciting medical breakthroughs travel fast, and small errors creep in as the findings pass from journals to news articles to social posts. Watch for specific-sounding statistics — exact patient counts, dose descriptions — that do not link back to a named study. When the real data is this impressive, invented details only muddy the water.
Sources
- Nature Medicine – Mackensen et al. (2022)
The original landmark study by Mackensen et al. published in Nature Medicine reported that 5 out of 5 patients with severe systemic lupus erythematosus (SLE) treated with CD19-targeted CAR T-cell therapy achieved drug-free remission, not 5 out of 6.
- Nature Medicine – Georg et al. (2024)
A follow-up study from the same Erlangen group expanded the cohort to 15 SLE patients and reported sustained remission in the majority, but the specific '5 of 6' framing does not match the published cohort sizes or results.
- The Lancet – Müller et al. / expanded CAR T lupus trials
Expanded reporting on CAR T-cell therapy in autoimmune diseases including lupus confirmed high remission rates but cohort numbers and dosing descriptions do not match a '5 of 6 lower dose' framing specifically.
- Science – News coverage of CAR T autoimmune trials
Science reporting on the Mackensen group's work described 5 patients achieving remission, not 5 of 6, and did not specifically characterize the dose as a 'lower dose' relative to a comparison arm.
- ClinicalTrials.gov – CAR T SLE trials
Registered trials for CAR T-cell therapy in SLE involve varying dose levels, but no published trial result matching exactly '5 of 6 patients at lower dose achieving remission' is identifiable in registered trial results.
Related debunks
- UnverifiableUnverified: The Claim That Only 250 Isolation Beds Exist Across Three Congo Provinces
- UnverifiableYes, Ebola Did Cross from Congo into Uganda — And Here's How It Was Stopped
- UnverifiableYes, Unregulated Stem Cell Clinics Have Caused Blindness, Tumors, and Infections — The FDA Has the Records to Prove It